<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>AIMS: Patients undergo ablation for focal <z:hpo ids='HP_0005110'>atrial fibrillation</z:hpo> (AF) as a result of failure of anti-arrhythmic drugs </plain></SENT>
<SENT sid="1" pm="."><plain>Our basic studies have implicated cholinergic and adrenergic neurotransmitter release as the underlying mechanism for focal AF </plain></SENT>
<SENT sid="2" pm="."><plain>Therefore, we tested the efficacy of a combination of <z:chebi fb="199" ids="26708">sodium</z:chebi> channel-blocking agents with additional vagolytic properties and a β-blocker to terminate and prevent focal AF </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND RESULTS: In 18 Na-<z:chebi fb="0" ids="7983">pentobarbital</z:chebi>-anaesthetized dogs, after a right or left thoracotomy, <z:chebi fb="9" ids="15355">acetylcholine</z:chebi> (<z:chebi fb="93" ids="22614">Ach</z:chebi>, 0.5 cc, 100 mM) was injected into a fat pad containing ganglionated plexi (GP) or applied on an atrial appendage (AA) to induce focal firing at the pulmonary veins (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PVs</z:e>) or AA, respectively </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="4657">Disopyramide</z:chebi> (2-4 mg/kg, n= 6) or <z:chebi fb="0" ids="28593">quinidine</z:chebi> (3-6 mg/kg, n= 12) combined with esmolol or <z:chebi fb="2" ids="8499">propranolol</z:chebi> (1 mg/kg, n= 13 and 5, respectively) were slowly injected to terminate (Group I, n= 12) or prevent (Group II, n= 6) <z:chebi fb="93" ids="22614">Ach</z:chebi>-induced sustained focal AF </plain></SENT>
<SENT sid="5" pm="."><plain>In another four dogs, only the <z:chebi fb="199" ids="26708">sodium</z:chebi> channel-blocking agents with additional vagolytic properties or only the β-blocker was injected prior to or after the initiation of focal AF </plain></SENT>
<SENT sid="6" pm="."><plain>At baseline, the mean duration of AF induced by <z:chebi fb="93" ids="22614">Ach</z:chebi> was 26 ± 4 min </plain></SENT>
<SENT sid="7" pm="."><plain>Group I: After drugs, <z:chebi fb="93" ids="22614">Ach</z:chebi>-induced AF duration was 3 ± 1 min (P&lt; 0.001) </plain></SENT>
<SENT sid="8" pm="."><plain>Group II: Prior to drugs, <z:chebi fb="93" ids="22614">Ach</z:chebi>-induced AF lasted for 19 ± 3 min </plain></SENT>
<SENT sid="9" pm="."><plain>With the drug combination the duration of <z:chebi fb="93" ids="22614">Ach</z:chebi>-induced AF, decreased to 6 ± 1/min, P&lt; 0.001 </plain></SENT>
<SENT sid="10" pm="."><plain>Either <z:chebi fb="0" ids="28593">quinidine</z:chebi> or <z:chebi fb="2" ids="8499">propranolol</z:chebi> alone did not change the duration of <z:chebi fb="93" ids="22614">Ach</z:chebi>-induced AF, mean 25 ± 10 min compared with <z:chebi fb="93" ids="22614">Ach</z:chebi> alone, 28 ± 16 min, P= 0.2 </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSIONS: Type IA (<z:chebi fb="0" ids="48873">cholinergic antagonist</z:chebi>) plus Type II (β-<z:chebi fb="0" ids="37887">adrenergic antagonist</z:chebi>) provides significant prevention and suppression of focal AF arising at <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> and non-<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">PV</z:e> sites </plain></SENT>
</text></document>